|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.19/3.17
|
企业价值
452.26M
|
资产负债 |
每股账面净值
1.89
|
现金流量 |
现金流量率
--
|
损益表 |
收益
14.02M
|
每股收益
0.10
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 07:01 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |